LBLTF (Lattice Biologics) Cyclically Adjusted Revenue per Share: $0.00 (As of Jun. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lattice Biologics Cyclically Adjusted Revenue per Share?

Lattice Biologics LBLTF -99.00% Cyclically Adjusted Revenue per Share is $0.00 as of Jun. 2021.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lattice Biologics's adjusted revenue per share for the three months ended in Jun. 2021 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Jun. 2021.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-15), Lattice Biologics's current stock price is $0.0001. Lattice Biologics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2021 was $0.00. Lattice Biologics's Cyclically Adjusted PS Ratio of today is .


Lattice Biologics  (OTCPK:LBLTF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lattice Biologics Cyclically Adjusted Revenue per Share Related Terms


Lattice Biologics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Lattice Biologics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lattice Biologics Cyclically Adjusted Revenue per Share Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LBLTF vs ABT, MDT, SYK: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Lattice Biologics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lattice Biologics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Cyclically Adjusted PS Ratio falls into.



Lattice Biologics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lattice Biologics's adjusted Revenue per Share data for the three months ended in Jun. 2021 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2021 (Change)*Current CPI (Jun. 2021)
=0/271.6960*271.6960
=0.000

Current CPI (Jun. 2021) = 271.6960.

Lattice Biologics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201109 0.000 226.889 0.000
201112 0.000 225.672 0.000
201203 0.000 229.392 0.000
201206 0.000 229.478 0.000
201209 0.000 231.407 0.000
201212 0.000 229.601 0.000
201303 0.000 232.773 0.000
201306 0.000 233.504 0.000
201309 0.000 234.149 0.000
201312 0.000 233.049 0.000
201403 0.000 236.293 0.000
201406 0.000 238.343 0.000
201409 0.000 238.031 0.000
201412 0.000 234.812 0.000
201503 0.000 236.119 0.000
201506 0.000 238.638 0.000
201509 0.000 237.945 0.000
201512 0.087 236.525 0.100
201603 0.021 238.132 0.024
201606 0.029 241.018 0.033
201609 0.013 241.428 0.015
201612 0.013 241.432 0.015
201703 0.010 243.801 0.011
201706 0.009 244.955 0.010
201709 0.004 246.819 0.004
201712 0.004 246.524 0.004
201803 0.003 249.554 0.003
201806 0.002 251.989 0.002
201809 0.003 252.439 0.003
201812 0.005 251.233 0.005
201903 0.008 254.202 0.009
201906 0.005 256.143 0.005
201909 0.006 256.759 0.006
201912 0.007 256.974 0.007
202003 0.005 258.115 0.005
202006 0.005 257.797 0.005
202009 0.006 260.280 0.006
202012 0.004 260.474 0.004
202103 0.002 264.877 0.002
202106 0.000 271.696 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Lattice Biologics (LBLTF) has a Cyclically Adjusted Revenue per Share of $0.00 as of Jun. 2021. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lattice Biologics and its competitors.
Is Lattice Biologics' Cyclically Adjusted Revenue per Share too high?
Lattice Biologics' current Cyclically Adjusted Revenue per Share is $0.00.
How does Lattice Biologics' Cyclically Adjusted Revenue per Share compare to ABT and MDT?
Lattice Biologics' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lattice Biologics and its competitors. Lattice Biologics's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current Cyclically Adjusted Revenue per Share is $0.00 as of Jun. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lattice Biologics Business Description

Address 512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The company's products include ADM dermis, DBM Putty, Bone scaffold, and others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.